Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Fiets, W. Edward
29  Ergebnisse:
Personensuche X
?
1

Assessing the clinical benefit of systemic anti-cancer trea..:

Leeneman, Brenda ; Xander, Nicolas S.H. ; Fiets, W. Edward...
European Journal of Cancer.  202 (2024)  - p. 114002 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Cost-effectiveness and budget impact of pembrolizumab+axiti..:

Xander, Nicolas S. H. ; Fiets, W. Edward ; Uyl-de Groot, Carin A.
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

Methotrexate plus or minus cetuximab as first‐line treatmen..:

Ham, Janneke C. ; van Meerten, Esther ; Fiets, W. Edward...
Head & Neck.  42 (2020)  5 - p. 828-838 , 2020
Link: https://doi.org/10.1002/..
 
?
4

Cost-effectiveness and budget impact of pembrolizumab+axiti..:

Xander, Nicolas S. H ; Fiets, W. Edward ; Uyl-de Groot, Carin A
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336227/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Adva..:

Rohaan, Maartje W ; Borch, Troels H ; van den Berg, Joost H...
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292.  , 2022
Link: https://hdl.handle.net/1..
 
?
6

Methotrexate plus or minus cetuximab as first‐line treatmen..:

Ham, Janneke C ; van Meerten, Esther ; Fiets, W. Edward...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216894/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
7

Methotrexate plus or minus cetuximab as first-line treatmen..:

Ham, Janneke C ; van Meerten, Esther ; Fiets, W. Edward...
Ham , J C , van Meerten , E , Fiets , W E , Beerepoot , L V , Jeurissen , F J F , Slingerland , M , Jonker , M A , Husson , O , van der Graaf , W T A & van Herpen , C M L 2020 , ' Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence ' , Head and Neck , vol. 42 , no. 5 , pp. 828-838 . https://doi.org/10.1002/hed.26053.  , 2020
Link: https://pure.eur.nl/en/p..
 
?
8

Lactate dehydrogenase as a selection criterion for ipilimum..:

Kelderman, Sander ; Heemskerk, Bianca ; van Tinteren, Harm...
Cancer Immunology, Immunotherapy.  , 2014
Link: https://doi.org/10.1007/..
 
?
9

Image_1_Cost-effectiveness and budget impact of pembrolizum..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
doi:10.3389/fonc.2023.1205700.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
10

Image_3_Cost-effectiveness and budget impact of pembrolizum..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
doi:10.3389/fonc.2023.1205700.s004.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Cost-effectiveness and budget impact of pembrolizumab+axiti..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
https://www.frontiersin.org/articles/10.3389/fonc.2023.1205700/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
12

Image_4_Cost-effectiveness and budget impact of pembrolizum..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
doi:10.3389/fonc.2023.1205700.s005.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Image_2_Cost-effectiveness and budget impact of pembrolizum..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
doi:10.3389/fonc.2023.1205700.s003.  , 2023
Link: https://doi.org/10.3389/..
 
?
14

DataSheet_1_Cost-effectiveness and budget impact of pembrol..:

Nicolas S. H. Xander ; W. Edward Fiets ; Carin A. Uyl-de Groot
doi:10.3389/fonc.2023.1205700.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
15

Androgen deprivation therapy for androgen receptor-positive..:

Boon, E. (Eline) ; van Boxtel, W. (Wim) ; Buter, J. (Jan)...
http://repub.eur.nl/pub/103642.  , 2017
Link: http://repub.eur.nl/pub/..
 
1-15